



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Orilanolimab

Cat. No.:	HY-P99791
CAS No.:	2066544-85-0
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity <sup>[1][2]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Interaction between FcRn and IgG <sup>[1]</sup>
<b>In Vitro</b>	Orilanolimab (10 nM, 50 nM, and 100 nM; 48 h) inhibits interferon IFN- $\gamma$ production in CD11c <sup>+</sup> Ag-presenting cells (APCs) from B2M <sup>TG/TG</sup> FCGRT <sup>TG/TG</sup> Fcgrt <sup>-/-</sup> mice <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Orilanolimab (20 mg/kg; i.v.) significantly reduces the plasma concentration of HuLys11 in mouse model <sup>[1]</sup> . Orilanolimab (10-100 mg/kg; i.v.; once per 5 weeks) causes dose-dependent and specific reduction of total circulating levels of IgG cynomolgus monkeys <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Blumberg LJ, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. *Sci Adv.* 2019 Dec 18;5(12):eaax9586.

[2]. Blumberg L, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases[J]. *Blood*, 2017, 130: 3483.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA